JP2016505065A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505065A5 JP2016505065A5 JP2015554265A JP2015554265A JP2016505065A5 JP 2016505065 A5 JP2016505065 A5 JP 2016505065A5 JP 2015554265 A JP2015554265 A JP 2015554265A JP 2015554265 A JP2015554265 A JP 2015554265A JP 2016505065 A5 JP2016505065 A5 JP 2016505065A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- peptide
- natriuretic peptide
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 108020001621 Natriuretic Peptide Proteins 0.000 claims 12
- 102000004571 Natriuretic peptide Human genes 0.000 claims 12
- 239000000692 natriuretic peptide Substances 0.000 claims 12
- 230000002526 effect on cardiovascular system Effects 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 101710158332 Diuretic hormone Proteins 0.000 claims 4
- 101710204261 Diuretic hormone class 2 Proteins 0.000 claims 4
- 108010001957 Ularitide Proteins 0.000 claims 4
- 102400001279 Urodilatin Human genes 0.000 claims 4
- 238000011156 evaluation Methods 0.000 claims 4
- IUCCYQIEZNQWRS-DWWHXVEHSA-N ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 claims 4
- 229940124549 vasodilator Drugs 0.000 claims 4
- 239000003071 vasodilator agent Substances 0.000 claims 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 3
- 206010007556 Cardiac failure acute Diseases 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 claims 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 2
- 108010074051 C-Reactive Protein Proteins 0.000 claims 2
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 claims 2
- 102100032752 C-reactive protein Human genes 0.000 claims 2
- 101800000060 C-type natriuretic peptide Proteins 0.000 claims 2
- 108010050286 Dendroaspis natriuretic peptide Proteins 0.000 claims 2
- 102400000686 Endothelin-1 Human genes 0.000 claims 2
- 101800004490 Endothelin-1 Proteins 0.000 claims 2
- 102000000802 Galectin 3 Human genes 0.000 claims 2
- 108010001517 Galectin 3 Proteins 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- -1 IL-1β Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 230000009635 nitrosylation Effects 0.000 claims 2
- 230000000304 vasodilatating effect Effects 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010064966 Myocardial oedema Diseases 0.000 claims 1
- 108090000103 Relaxin Proteins 0.000 claims 1
- 102000003743 Relaxin Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001267 nesiritide Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361756692P | 2013-01-25 | 2013-01-25 | |
| US61/756,692 | 2013-01-25 | ||
| PCT/IB2014/000253 WO2014115033A2 (en) | 2013-01-25 | 2014-01-24 | Methods of treating cardiovascular indications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016505065A JP2016505065A (ja) | 2016-02-18 |
| JP2016505065A5 true JP2016505065A5 (cg-RX-API-DMAC10.html) | 2016-12-01 |
Family
ID=50382492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015554265A Pending JP2016505065A (ja) | 2013-01-25 | 2014-01-24 | 心血管症候の治療方法 |
Country Status (19)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015184248A1 (en) * | 2014-05-30 | 2015-12-03 | Concert Pharmaceuticals, Inc. | Methods of treating fibrotic diseases |
| CN105617360B (zh) * | 2015-12-04 | 2018-12-21 | 中国农业大学 | C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用 |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| CN110278941B (zh) * | 2019-07-11 | 2021-05-28 | 西安国际医学中心有限公司 | 一种含有钠尿肽的离体心脏保护液 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346953A1 (de) | 1983-12-24 | 1985-08-14 | Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg | Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung |
| US5449751A (en) | 1987-03-02 | 1995-09-12 | Pharma Bissendorf Peptide Gmbh | Cardiodilatin fragment, process for preparing same and use thereof |
| US5461142A (en) | 1987-11-07 | 1995-10-24 | Pharma Bissendorf Peptide Gmbh | Phosphorylated derivatives of cardiodilatin/ANF peptides |
| US5166191A (en) * | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
| DE4216133A1 (de) | 1992-05-15 | 1993-11-18 | Bissendorf Peptide Gmbh | Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen |
| WO1995033769A1 (de) | 1994-06-02 | 1995-12-14 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung |
| DE19951471A1 (de) | 1999-10-26 | 2001-05-03 | Forssmann Wolf Georg | Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen |
| US6407211B1 (en) * | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
| JP2004510743A (ja) * | 2000-10-04 | 2004-04-08 | モレキュラー メディシン リサーチ インスティチュート | レラキシンのアゴニストまたはアンタゴニストの投与によるアポトーシスを調節する方法 |
| KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| US20050113286A1 (en) * | 2002-03-18 | 2005-05-26 | Schreiner George F. | Methods for treating congestive heart failure |
| US7732406B2 (en) * | 2005-04-07 | 2010-06-08 | Cardiopep Pharma Gmbh | Use of natriuretic peptide for treating heart failure |
| WO2009034134A2 (en) * | 2007-09-11 | 2009-03-19 | Pharis Biotec Gmbh | Use of natriuretic peptides for treating angioedema syndromes |
| WO2009086126A2 (en) * | 2007-12-21 | 2009-07-09 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
| AU2009246112B2 (en) * | 2008-05-16 | 2013-05-02 | Corthera, Inc. | Method of treating chronic heart failure |
| US8642550B2 (en) * | 2008-10-24 | 2014-02-04 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides without hypotensive inducing capability |
| JP2010116325A (ja) * | 2008-11-11 | 2010-05-27 | Institute For Protein Science Co Ltd | Ｓｉｒｓ患者を救命するためのペプチド組成物 |
| US20110014180A1 (en) * | 2009-07-16 | 2011-01-20 | Masafumi Koide | Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue |
| PH12012500562A1 (en) * | 2009-09-25 | 2012-10-22 | Takeda Pharmaceuticals Co | Novel npr-b antagonists |
| US8551938B2 (en) * | 2009-09-25 | 2013-10-08 | Alcon Research, Ltd. | NPR-B agonists |
| EP2547356A1 (en) * | 2010-03-15 | 2013-01-23 | Wolf-Georg Forssmann | Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound |
| EP2605797A2 (en) * | 2010-08-20 | 2013-06-26 | Cerulean Pharma Inc. | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
-
2014
- 2014-01-24 NZ NZ710246A patent/NZ710246A/en not_active IP Right Cessation
- 2014-01-24 CA CA2898571A patent/CA2898571A1/en not_active Abandoned
- 2014-01-24 SG SG11201505492XA patent/SG11201505492XA/en unknown
- 2014-01-24 JP JP2015554265A patent/JP2016505065A/ja active Pending
- 2014-01-24 BR BR112015017432A patent/BR112015017432A2/pt not_active IP Right Cessation
- 2014-01-24 US US14/163,273 patent/US20140213520A1/en not_active Abandoned
- 2014-01-24 AU AU2014208851A patent/AU2014208851B2/en not_active Ceased
- 2014-01-24 AP AP2015008624A patent/AP2015008624A0/xx unknown
- 2014-01-24 MX MX2015009606A patent/MX2015009606A/es unknown
- 2014-01-24 KR KR1020157022509A patent/KR20150108903A/ko not_active Withdrawn
- 2014-01-24 TW TW103102790A patent/TW201442722A/zh unknown
- 2014-01-24 CN CN201480013163.1A patent/CN105025918A/zh active Pending
- 2014-01-24 US US14/163,130 patent/US20140213519A1/en not_active Abandoned
- 2014-01-24 WO PCT/IB2014/000253 patent/WO2014115033A2/en not_active Ceased
- 2014-01-24 EP EP14712761.7A patent/EP2948165A2/en not_active Withdrawn
- 2014-01-24 EA EA201500765A patent/EA201500765A1/ru unknown
-
2015
- 2015-07-13 PH PH12015501559A patent/PH12015501559A1/en unknown
- 2015-07-13 IL IL239909A patent/IL239909A0/en unknown
- 2015-07-23 TN TN2015000315A patent/TN2015000315A1/en unknown
- 2015-07-24 DO DO2015000175A patent/DOP2015000175A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fu et al. | Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure | |
| Kasama et al. | Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction | |
| Gupta et al. | Natriuretic peptides and cardiometabolic health | |
| Díez | Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy | |
| CN103212063B (zh) | 用松弛素治疗与急性心力衰竭相关的呼吸困难 | |
| Del Ry et al. | Recent advances on natriuretic peptide system: new promising therapeutic targets for the treatment of heart failure | |
| JP2017061453A5 (cg-RX-API-DMAC10.html) | ||
| Szczepanska-Sadowska et al. | Vasopressin and related peptides; potential value in diagnosis, prognosis and treatment of clinical disorders | |
| Del Ry et al. | Natriuretic peptide system and the heart | |
| Du et al. | Therapeutic Effects of Serelaxin in Acute Heart Failure–Necessity for Bilateral Research Translation– | |
| JP5948683B2 (ja) | 悪性腫瘍転移抑制用医薬 | |
| Pagel-Langenickel | Evolving role of natriuretic peptides from diagnostic tool to therapeutic modality | |
| Kępińska et al. | Advanced heart failure: A review | |
| Rocha et al. | Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials | |
| Zamani et al. | Novel vasodilators in heart failure | |
| Fu et al. | Therapeutic progress and knowledge basis on the natriuretic peptide system in heart failure | |
| RU2017142779A (ru) | Перенос гена cmlck | |
| Liczek et al. | Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Response to the letter of Siniorakis et al | |
| Skvortsov et al. | Therapy of High Risk Patients After Decompensation of Heart Failure Under NT-proBNP Control. Main Results | |
| Pemberton et al. | Cardiac natriuretic peptides | |
| Toma et al. | Evolution of arterial hypertension in patients with hepatitis C virus cirrhosis after antiviral treatment | |
| Sasaoka et al. | Low dose carperitide (alpha-hANP) administration is effective for preventing worsening renal function (WRF) and long-term renal protection | |
| Bekele | Natriuretic Peptide Receptors (NPRs) as a Potential Target for the Treatment of Heart Failure | |
| Jackson et al. | Inflammation and cardio-renal interactions in heart failure: a potential role for interleukin-6 | |
| Abdulla et al. | Cardiac and circulatory problems |